Yumanity Therapeutics announced that its investigational therapy, YTX-7739, worked to safely inhibit stearoyl-CoA desaturase — an enzyme thought to play a role in the alpha-synuclein-derived toxicity seen in Parkinson’s — in a Phase 1b clinical trial in people with mild-to-moderate disease. Data from this trial, conduced in the Netherlands, is…
Gain Therapeutics announced that preclinical studies with two of its compounds, GT-02287 and GT-02329, showed they could reduce the alpha-synuclein aggregates that characterize Parkinson’s and increase glucocerebrosidase protein levels in cell models of Parkinson’s and Gaucher disease. GT-02287 and GT-02329 are known as STARs, which stands for structurally targeted…
A gene therapy targeting the substantia nigra, the brain region with dopamine-producing nerve cells, may boost the benefits of levodopa for people with Parkinson’s disease, a study reports. This idea was tested in a new mouse disease model — one in which Parkinson’s symptoms appeared after disrupting a protein…
By lessening the involuntary movements, called dyskinesia, experienced by people with advanced Parkinson’s disease, treatment with AbbVie’s Duodopa (levodopa-carbidopa intestinal gel) was linked with better health-related quality of life, according to a post-hoc analysis of a clinical trial. Duodopa treatment also was tied to other added benefits, namely…
A new, potent inhibitor of the Bach1 protein — whose levels are elevated in brain tissue of Parkinson’s disease patients — showed neuroprotective effects in lab tests and lessened symptoms in a mouse model of acute Parkinson’s, a study found. Most importantly, the inhibitor had therapeutic potential when administered…
ABBV-0805, AbbVie’s experimental antibody-based therapy for Parkinson’s disease, selectively binds to toxic clumps of the alpha-synuclein protein — a hallmark of the disease — preventing their spread and prolonging survival in mouse models of Parkinson’s, a study shows. Also, the investigational antibody was found to bind to harmful…
Treatment with the investigational therapy CST-103 increased blood flow to certain regions of the brains of people with Parkinson’s disease and mild cognitive impairment, results of a small clinical trial show. The type of increased blood flow that was seen “correlates with increased neuronal activity and cognitive benefit,” Gabriel…
An investigational therapy, ATH434 was able to reverse some gastrointestinal problems in a mouse model of Parkinson’s disease, according to its developer Alterity Therapeutics. “Practicing clinicians are well aware of the substantial impact that these symptoms have on the quality of life of individuals with Parkinson’s disease,” David Stamler,…
The active agent in Solace PS128, a probiotic sold by Oryx Biomedical, eased disease symptoms and improved life quality in 25 people with Parkinson’s disease given the supplement in a small, open-label clinical trial. “Solace PS128 is the result of more than 20 years of scientific research,” David…
Scientists from Northwestern University will use two grants — totaling $17.9 million — from the Aligning Science Across Parkinson’s (ASAP) initiative to study alterations in the brain that contribute to the development of Parkinson’s disease. Their research focuses on brain circuits, the specific populations of interconnected brain cells…
Get regular updates to your inbox.
